Lonza extends collaboration with global biopharmaceutical partner for commercial-scale manufacture of ADCs

Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC

Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate

GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally

Aster implements India’s first IOeRT for cancer care

To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients

Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn

Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio

Zydus and Dr. Reddy's announce licensing agreement for co?marketing of Pertuzumab biosimilar

AbbVie announces positive results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine for high FR? expressing platinum-sensitive ovarian cancer

PICCOLO trial met its primary endpoint of objective response rate (ORR)

AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore

Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer

Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2

NATCO invests US$ 2 million in Cellogen Therapeutics

Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy

Kokilaben Dhirubhai Ambani Hospital introduces revolutionary HIFU Technology for prostate cancer treatment

HIFU is a state-of-the-art treatment that utilizes high-frequency sound waves to target and destroy prostate cancer cells